AustralieFrV1, Main, Exploration, bibRecord, 002703

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.

Identifieur interne : 002703 ( Main/Exploration ); précédent : 002702; suivant : 002704

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.

Auteurs : Paul Ruff [Afrique du Sud] ; David R. Ferry [Royaume-Uni] ; Radek Lakom [République tchèque] ; Jana Prausová [République tchèque] ; Guy A. Van Hazel [Australie] ; Paulo M. Hoff [Brésil] ; David Cunningham [Royaume-Uni] ; Dirk Arnold [Allemagne] ; Hans J. Schmoll [Allemagne] ; Vladimir M. Moiseyenko [Russie] ; Joseph J. Mckendrick [Australie] ; Albert J. Ten Tije [Pays-Bas] ; Raghu L. Vishwanath [États-Unis] ; Pankaj Bhargava [États-Unis] ; Soazig Chevalier [France] ; Teresa Macarulla [Espagne] ; Eric Van Cutsem [Belgique]

Source :

European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2015.

RBID : pubmed:25466509

Descripteurs français

English descriptors

KwdEn :
- Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (pharmacology), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Biomarkers, Pharmacological, Camptothecin (adverse effects), Camptothecin (analogs & derivatives), Camptothecin (pharmacology), Camptothecin (therapeutic use), Colorectal Neoplasms (pathology), Disease Progression, Disease-Free Survival, Female, Fluorouracil (adverse effects), Fluorouracil (pharmacology), Fluorouracil (therapeutic use), Humans, Leucovorin (adverse effects), Leucovorin (pharmacology), Leucovorin (therapeutic use), Male, Neoplasm Metastasis, Organoplatinum Compounds (therapeutic use), Proportional Hazards Models, Receptors, Vascular Endothelial Growth Factor (adverse effects), Receptors, Vascular Endothelial Growth Factor (pharmacology), Receptors, Vascular Endothelial Growth Factor (therapeutic use), Recombinant Fusion Proteins (adverse effects), Recombinant Fusion Proteins (therapeutic use).
MESH :
- chemical , adverse effects : Camptothecin, Fluorouracil, Leucovorin, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins.
- chemical , analogs & derivatives : Camptothecin.
- chemical , pharmacology : Camptothecin, Fluorouracil, Leucovorin, Receptors, Vascular Endothelial Growth Factor.
- chemical , therapeutic use : Camptothecin, Fluorouracil, Leucovorin, Organoplatinum Compounds, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins.
- chemical : Biomarkers, Pharmacological.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- pathology : Colorectal Neoplasms.
- pharmacology : Antineoplastic Combined Chemotherapy Protocols.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Disease Progression, Disease-Free Survival, Female, Humans, Male, Neoplasm Metastasis, Proportional Hazards Models.

Abstract

Patients with metastatic colorectal cancer (mCRC) previously-treated with oxaliplatin benefit significantly from the addition of aflibercept to FOLFIRI in relation to overall survival, progression-free survival and response rate.

DOI: 10.1016/j.ejca.2014.10.019
PubMed: 25466509

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.</title>
<author><name sortKey="Ruff, Paul" sort="Ruff, Paul" uniqKey="Ruff P" first="Paul" last="Ruff">Paul Ruff</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Witwatersrand, Faculty of Health Sciences, Johannesburg, South Africa. Electronic address: pruff@iafrica.com.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>University of Witwatersrand, Faculty of Health Sciences, Johannesburg</wicri:regionArea>
<wicri:noRegion>Johannesburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ferry, David R" sort="Ferry, David R" uniqKey="Ferry D" first="David R" last="Ferry">David R. Ferry</name>
<affiliation wicri:level="1"><nlm:affiliation>Russells Hall Hospital, Dudley, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Russells Hall Hospital, Dudley</wicri:regionArea>
<wicri:noRegion>Dudley</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lakom, Radek" sort="Lakom, Radek" uniqKey="Lakom R" first="Radek" last="Lakom">Radek Lakom</name>
<affiliation wicri:level="3"><nlm:affiliation>Masaryk Memorial Cancer Institute, Brno, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Masaryk Memorial Cancer Institute, Brno</wicri:regionArea>
<placeName><settlement type="city">Brno</settlement>
<region>Moravie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Prausova, Jana" sort="Prausova, Jana" uniqKey="Prausova J" first="Jana" last="Prausová">Jana Prausová</name>
<affiliation wicri:level="3"><nlm:affiliation>Fakultni nemocnice v Motole, Praha, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Fakultni nemocnice v Motole, Praha</wicri:regionArea>
<placeName><settlement type="city">Prague</settlement>
<region type="région" nuts="2">Bohême centrale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Hazel, Guy A" sort="Van Hazel, Guy A" uniqKey="Van Hazel G" first="Guy A" last="Van Hazel">Guy A. Van Hazel</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Western Australia, Western Australia, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>University of Western Australia, Western Australia</wicri:regionArea>
<wicri:noRegion>Western Australia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hoff, Paulo M" sort="Hoff, Paulo M" uniqKey="Hoff P" first="Paulo M" last="Hoff">Paulo M. Hoff</name>
<affiliation wicri:level="3"><nlm:affiliation>Centro De Oncologia/Hospital Sirio Libanes, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Centro De Oncologia/Hospital Sirio Libanes, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cunningham, David" sort="Cunningham, David" uniqKey="Cunningham D" first="David" last="Cunningham">David Cunningham</name>
<affiliation wicri:level="1"><nlm:affiliation>The Royal Marsden Hospital, Sutton, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Royal Marsden Hospital, Sutton</wicri:regionArea>
<wicri:noRegion>Sutton</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Arnold, Dirk" sort="Arnold, Dirk" uniqKey="Arnold D" first="Dirk" last="Arnold">Dirk Arnold</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Tumor Biology Center, Freiburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Medical Oncology, Tumor Biology Center, Freiburg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Fribourg-en-Brisgau</region>
<settlement type="city">Fribourg-en-Brisgau</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schmoll, Hans J" sort="Schmoll, Hans J" uniqKey="Schmoll H" first="Hans J" last="Schmoll">Hans J. Schmoll</name>
<affiliation wicri:level="1"><nlm:affiliation>Martin Luther University Halle-Wittenberg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Martin Luther University Halle-Wittenberg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moiseyenko, Vladimir M" sort="Moiseyenko, Vladimir M" uniqKey="Moiseyenko V" first="Vladimir M" last="Moiseyenko">Vladimir M. Moiseyenko</name>
<affiliation wicri:level="1"><nlm:affiliation>Oncology Research Institute Na. NN. Petrov, St-Petersburg, Russian Federation.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Oncology Research Institute Na. NN. Petrov, St-Petersburg</wicri:regionArea>
<wicri:noRegion>St-Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mckendrick, Joseph J" sort="Mckendrick, Joseph J" uniqKey="Mckendrick J" first="Joseph J" last="Mckendrick">Joseph J. Mckendrick</name>
<affiliation wicri:level="1"><nlm:affiliation>Monash University, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Monash University, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ten Tije, Albert J" sort="Ten Tije, Albert J" uniqKey="Ten Tije A" first="Albert J" last="Ten Tije">Albert J. Ten Tije</name>
<affiliation wicri:level="1"><nlm:affiliation>Amphia Hospital, Breda, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Amphia Hospital, Breda</wicri:regionArea>
<wicri:noRegion>Breda</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vishwanath, Raghu L" sort="Vishwanath, Raghu L" uniqKey="Vishwanath R" first="Raghu L" last="Vishwanath">Raghu L. Vishwanath</name>
<affiliation wicri:level="2"><nlm:affiliation>Sanofi Global Oncology Medical Affairs, Cambridge, MA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sanofi Global Oncology Medical Affairs, Cambridge, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bhargava, Pankaj" sort="Bhargava, Pankaj" uniqKey="Bhargava P" first="Pankaj" last="Bhargava">Pankaj Bhargava</name>
<affiliation wicri:level="2"><nlm:affiliation>Sanofi Global Oncology Research and Development, Cambridge, MA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sanofi Global Oncology Research and Development, Cambridge, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chevalier, Soazig" sort="Chevalier, Soazig" uniqKey="Chevalier S" first="Soazig" last="Chevalier">Soazig Chevalier</name>
<affiliation wicri:level="1"><nlm:affiliation>Sanofi, Vitry-sur-Seine, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Sanofi, Vitry-sur-Seine</wicri:regionArea>
<wicri:noRegion>Vitry-sur-Seine</wicri:noRegion>
<wicri:noRegion>Vitry-sur-Seine</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Macarulla, Teresa" sort="Macarulla, Teresa" uniqKey="Macarulla T" first="Teresa" last="Macarulla">Teresa Macarulla</name>
<affiliation wicri:level="3"><nlm:affiliation>Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name>
<affiliation wicri:level="1"><nlm:affiliation>University Hospitals Leuven and KU Leuven, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>University Hospitals Leuven and KU Leuven</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25466509</idno>
<idno type="pmid">25466509</idno>
<idno type="doi">10.1016/j.ejca.2014.10.019</idno>
<idno type="wicri:Area/PubMed/Corpus">003185</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003185</idno>
<idno type="wicri:Area/PubMed/Curation">003075</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003075</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003075</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003075</idno>
<idno type="wicri:Area/Ncbi/Merge">002057</idno>
<idno type="wicri:Area/Ncbi/Curation">002057</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002057</idno>
<idno type="wicri:Area/Main/Merge">002703</idno>
<idno type="wicri:Area/Main/Curation">002703</idno>
<idno type="wicri:Area/Main/Exploration">002703</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.</title>
<author><name sortKey="Ruff, Paul" sort="Ruff, Paul" uniqKey="Ruff P" first="Paul" last="Ruff">Paul Ruff</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Witwatersrand, Faculty of Health Sciences, Johannesburg, South Africa. Electronic address: pruff@iafrica.com.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>University of Witwatersrand, Faculty of Health Sciences, Johannesburg</wicri:regionArea>
<wicri:noRegion>Johannesburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ferry, David R" sort="Ferry, David R" uniqKey="Ferry D" first="David R" last="Ferry">David R. Ferry</name>
<affiliation wicri:level="1"><nlm:affiliation>Russells Hall Hospital, Dudley, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Russells Hall Hospital, Dudley</wicri:regionArea>
<wicri:noRegion>Dudley</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lakom, Radek" sort="Lakom, Radek" uniqKey="Lakom R" first="Radek" last="Lakom">Radek Lakom</name>
<affiliation wicri:level="3"><nlm:affiliation>Masaryk Memorial Cancer Institute, Brno, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Masaryk Memorial Cancer Institute, Brno</wicri:regionArea>
<placeName><settlement type="city">Brno</settlement>
<region>Moravie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Prausova, Jana" sort="Prausova, Jana" uniqKey="Prausova J" first="Jana" last="Prausová">Jana Prausová</name>
<affiliation wicri:level="3"><nlm:affiliation>Fakultni nemocnice v Motole, Praha, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Fakultni nemocnice v Motole, Praha</wicri:regionArea>
<placeName><settlement type="city">Prague</settlement>
<region type="région" nuts="2">Bohême centrale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Hazel, Guy A" sort="Van Hazel, Guy A" uniqKey="Van Hazel G" first="Guy A" last="Van Hazel">Guy A. Van Hazel</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Western Australia, Western Australia, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>University of Western Australia, Western Australia</wicri:regionArea>
<wicri:noRegion>Western Australia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hoff, Paulo M" sort="Hoff, Paulo M" uniqKey="Hoff P" first="Paulo M" last="Hoff">Paulo M. Hoff</name>
<affiliation wicri:level="3"><nlm:affiliation>Centro De Oncologia/Hospital Sirio Libanes, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Centro De Oncologia/Hospital Sirio Libanes, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cunningham, David" sort="Cunningham, David" uniqKey="Cunningham D" first="David" last="Cunningham">David Cunningham</name>
<affiliation wicri:level="1"><nlm:affiliation>The Royal Marsden Hospital, Sutton, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Royal Marsden Hospital, Sutton</wicri:regionArea>
<wicri:noRegion>Sutton</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Arnold, Dirk" sort="Arnold, Dirk" uniqKey="Arnold D" first="Dirk" last="Arnold">Dirk Arnold</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Tumor Biology Center, Freiburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Medical Oncology, Tumor Biology Center, Freiburg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Fribourg-en-Brisgau</region>
<settlement type="city">Fribourg-en-Brisgau</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schmoll, Hans J" sort="Schmoll, Hans J" uniqKey="Schmoll H" first="Hans J" last="Schmoll">Hans J. Schmoll</name>
<affiliation wicri:level="1"><nlm:affiliation>Martin Luther University Halle-Wittenberg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Martin Luther University Halle-Wittenberg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moiseyenko, Vladimir M" sort="Moiseyenko, Vladimir M" uniqKey="Moiseyenko V" first="Vladimir M" last="Moiseyenko">Vladimir M. Moiseyenko</name>
<affiliation wicri:level="1"><nlm:affiliation>Oncology Research Institute Na. NN. Petrov, St-Petersburg, Russian Federation.</nlm:affiliation>
<country xml:lang="fr">Russie</country>
<wicri:regionArea>Oncology Research Institute Na. NN. Petrov, St-Petersburg</wicri:regionArea>
<wicri:noRegion>St-Petersburg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mckendrick, Joseph J" sort="Mckendrick, Joseph J" uniqKey="Mckendrick J" first="Joseph J" last="Mckendrick">Joseph J. Mckendrick</name>
<affiliation wicri:level="1"><nlm:affiliation>Monash University, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Monash University, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ten Tije, Albert J" sort="Ten Tije, Albert J" uniqKey="Ten Tije A" first="Albert J" last="Ten Tije">Albert J. Ten Tije</name>
<affiliation wicri:level="1"><nlm:affiliation>Amphia Hospital, Breda, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Amphia Hospital, Breda</wicri:regionArea>
<wicri:noRegion>Breda</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vishwanath, Raghu L" sort="Vishwanath, Raghu L" uniqKey="Vishwanath R" first="Raghu L" last="Vishwanath">Raghu L. Vishwanath</name>
<affiliation wicri:level="2"><nlm:affiliation>Sanofi Global Oncology Medical Affairs, Cambridge, MA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sanofi Global Oncology Medical Affairs, Cambridge, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bhargava, Pankaj" sort="Bhargava, Pankaj" uniqKey="Bhargava P" first="Pankaj" last="Bhargava">Pankaj Bhargava</name>
<affiliation wicri:level="2"><nlm:affiliation>Sanofi Global Oncology Research and Development, Cambridge, MA, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sanofi Global Oncology Research and Development, Cambridge, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chevalier, Soazig" sort="Chevalier, Soazig" uniqKey="Chevalier S" first="Soazig" last="Chevalier">Soazig Chevalier</name>
<affiliation wicri:level="1"><nlm:affiliation>Sanofi, Vitry-sur-Seine, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Sanofi, Vitry-sur-Seine</wicri:regionArea>
<wicri:noRegion>Vitry-sur-Seine</wicri:noRegion>
<wicri:noRegion>Vitry-sur-Seine</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Macarulla, Teresa" sort="Macarulla, Teresa" uniqKey="Macarulla T" first="Teresa" last="Macarulla">Teresa Macarulla</name>
<affiliation wicri:level="3"><nlm:affiliation>Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name>
<affiliation wicri:level="1"><nlm:affiliation>University Hospitals Leuven and KU Leuven, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>University Hospitals Leuven and KU Leuven</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">European journal of cancer (Oxford, England : 1990)</title>
<idno type="eISSN">1879-0852</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (pharmacology)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Biomarkers, Pharmacological</term>
<term>Camptothecin (adverse effects)</term>
<term>Camptothecin (analogs & derivatives)</term>
<term>Camptothecin (pharmacology)</term>
<term>Camptothecin (therapeutic use)</term>
<term>Colorectal Neoplasms (pathology)</term>
<term>Disease Progression</term>
<term>Disease-Free Survival</term>
<term>Female</term>
<term>Fluorouracil (adverse effects)</term>
<term>Fluorouracil (pharmacology)</term>
<term>Fluorouracil (therapeutic use)</term>
<term>Humans</term>
<term>Leucovorin (adverse effects)</term>
<term>Leucovorin (pharmacology)</term>
<term>Leucovorin (therapeutic use)</term>
<term>Male</term>
<term>Neoplasm Metastasis</term>
<term>Organoplatinum Compounds (therapeutic use)</term>
<term>Proportional Hazards Models</term>
<term>Receptors, Vascular Endothelial Growth Factor (adverse effects)</term>
<term>Receptors, Vascular Endothelial Growth Factor (pharmacology)</term>
<term>Receptors, Vascular Endothelial Growth Factor (therapeutic use)</term>
<term>Recombinant Fusion Proteins (adverse effects)</term>
<term>Recombinant Fusion Proteins (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Biomarqueurs pharmacologiques</term>
<term>Camptothécine (analogues et dérivés)</term>
<term>Camptothécine (effets indésirables)</term>
<term>Camptothécine (pharmacologie)</term>
<term>Camptothécine (usage thérapeutique)</term>
<term>Composés organiques du platine (usage thérapeutique)</term>
<term>Femelle</term>
<term>Fluorouracil (effets indésirables)</term>
<term>Fluorouracil (pharmacologie)</term>
<term>Fluorouracil (usage thérapeutique)</term>
<term>Humains</term>
<term>Leucovorine (effets indésirables)</term>
<term>Leucovorine (pharmacologie)</term>
<term>Leucovorine (usage thérapeutique)</term>
<term>Modèles de hasards proportionnels</term>
<term>Mâle</term>
<term>Métastase tumorale</term>
<term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (pharmacologie)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Protéines de fusion recombinantes (effets indésirables)</term>
<term>Protéines de fusion recombinantes (usage thérapeutique)</term>
<term>Récepteurs aux facteurs de croissance endothéliale vasculaire (effets indésirables)</term>
<term>Récepteurs aux facteurs de croissance endothéliale vasculaire (pharmacologie)</term>
<term>Récepteurs aux facteurs de croissance endothéliale vasculaire (usage thérapeutique)</term>
<term>Survie sans rechute</term>
<term>Tumeurs colorectales (anatomopathologie)</term>
<term>Évolution de la maladie</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Camptothecin</term>
<term>Fluorouracil</term>
<term>Leucovorin</term>
<term>Receptors, Vascular Endothelial Growth Factor</term>
<term>Recombinant Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Camptothecin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Camptothecin</term>
<term>Fluorouracil</term>
<term>Leucovorin</term>
<term>Receptors, Vascular Endothelial Growth Factor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Camptothecin</term>
<term>Fluorouracil</term>
<term>Leucovorin</term>
<term>Organoplatinum Compounds</term>
<term>Receptors, Vascular Endothelial Growth Factor</term>
<term>Recombinant Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Biomarkers, Pharmacological</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Camptothécine</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs colorectales</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Camptothécine</term>
<term>Fluorouracil</term>
<term>Leucovorine</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Protéines de fusion recombinantes</term>
<term>Récepteurs aux facteurs de croissance endothéliale vasculaire</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Colorectal Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Camptothécine</term>
<term>Fluorouracil</term>
<term>Leucovorine</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Récepteurs aux facteurs de croissance endothéliale vasculaire</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Camptothécine</term>
<term>Composés organiques du platine</term>
<term>Fluorouracil</term>
<term>Leucovorine</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Protéines de fusion recombinantes</term>
<term>Récepteurs aux facteurs de croissance endothéliale vasculaire</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term>
<term>Disease-Free Survival</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Neoplasm Metastasis</term>
<term>Proportional Hazards Models</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Biomarqueurs pharmacologiques</term>
<term>Femelle</term>
<term>Humains</term>
<term>Modèles de hasards proportionnels</term>
<term>Mâle</term>
<term>Métastase tumorale</term>
<term>Survie sans rechute</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Patients with metastatic colorectal cancer (mCRC) previously-treated with oxaliplatin benefit significantly from the addition of aflibercept to FOLFIRI in relation to overall survival, progression-free survival and response rate.</div>
</front>
</TEI>
<affiliations><list><country><li>Afrique du Sud</li>
<li>Allemagne</li>
<li>Australie</li>
<li>Belgique</li>
<li>Brésil</li>
<li>Espagne</li>
<li>France</li>
<li>Pays-Bas</li>
<li>Royaume-Uni</li>
<li>Russie</li>
<li>République tchèque</li>
<li>États-Unis</li>
</country>
<region><li>Bade-Wurtemberg</li>
<li>Bohême centrale</li>
<li>Catalogne</li>
<li>District de Fribourg-en-Brisgau</li>
<li>Massachusetts</li>
<li>Moravie</li>
<li>État de São Paulo</li>
</region>
<settlement><li>Barcelone</li>
<li>Brno</li>
<li>Fribourg-en-Brisgau</li>
<li>Prague</li>
<li>São Paulo</li>
</settlement>
</list>
<tree><country name="Afrique du Sud"><noRegion><name sortKey="Ruff, Paul" sort="Ruff, Paul" uniqKey="Ruff P" first="Paul" last="Ruff">Paul Ruff</name>
</noRegion>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Ferry, David R" sort="Ferry, David R" uniqKey="Ferry D" first="David R" last="Ferry">David R. Ferry</name>
</noRegion>
<name sortKey="Cunningham, David" sort="Cunningham, David" uniqKey="Cunningham D" first="David" last="Cunningham">David Cunningham</name>
</country>
<country name="République tchèque"><region name="Moravie"><name sortKey="Lakom, Radek" sort="Lakom, Radek" uniqKey="Lakom R" first="Radek" last="Lakom">Radek Lakom</name>
</region>
<name sortKey="Prausova, Jana" sort="Prausova, Jana" uniqKey="Prausova J" first="Jana" last="Prausová">Jana Prausová</name>
</country>
<country name="Australie"><noRegion><name sortKey="Van Hazel, Guy A" sort="Van Hazel, Guy A" uniqKey="Van Hazel G" first="Guy A" last="Van Hazel">Guy A. Van Hazel</name>
</noRegion>
<name sortKey="Mckendrick, Joseph J" sort="Mckendrick, Joseph J" uniqKey="Mckendrick J" first="Joseph J" last="Mckendrick">Joseph J. Mckendrick</name>
</country>
<country name="Brésil"><region name="État de São Paulo"><name sortKey="Hoff, Paulo M" sort="Hoff, Paulo M" uniqKey="Hoff P" first="Paulo M" last="Hoff">Paulo M. Hoff</name>
</region>
</country>
<country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Arnold, Dirk" sort="Arnold, Dirk" uniqKey="Arnold D" first="Dirk" last="Arnold">Dirk Arnold</name>
</region>
<name sortKey="Schmoll, Hans J" sort="Schmoll, Hans J" uniqKey="Schmoll H" first="Hans J" last="Schmoll">Hans J. Schmoll</name>
</country>
<country name="Russie"><noRegion><name sortKey="Moiseyenko, Vladimir M" sort="Moiseyenko, Vladimir M" uniqKey="Moiseyenko V" first="Vladimir M" last="Moiseyenko">Vladimir M. Moiseyenko</name>
</noRegion>
</country>
<country name="Pays-Bas"><noRegion><name sortKey="Ten Tije, Albert J" sort="Ten Tije, Albert J" uniqKey="Ten Tije A" first="Albert J" last="Ten Tije">Albert J. Ten Tije</name>
</noRegion>
</country>
<country name="États-Unis"><region name="Massachusetts"><name sortKey="Vishwanath, Raghu L" sort="Vishwanath, Raghu L" uniqKey="Vishwanath R" first="Raghu L" last="Vishwanath">Raghu L. Vishwanath</name>
</region>
<name sortKey="Bhargava, Pankaj" sort="Bhargava, Pankaj" uniqKey="Bhargava P" first="Pankaj" last="Bhargava">Pankaj Bhargava</name>
</country>
<country name="France"><noRegion><name sortKey="Chevalier, Soazig" sort="Chevalier, Soazig" uniqKey="Chevalier S" first="Soazig" last="Chevalier">Soazig Chevalier</name>
</noRegion>
</country>
<country name="Espagne"><region name="Catalogne"><name sortKey="Macarulla, Teresa" sort="Macarulla, Teresa" uniqKey="Macarulla T" first="Teresa" last="Macarulla">Teresa Macarulla</name>
</region>
</country>
<country name="Belgique"><noRegion><name sortKey="Van Cutsem, Eric" sort="Van Cutsem, Eric" uniqKey="Van Cutsem E" first="Eric" last="Van Cutsem">Eric Van Cutsem</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002703 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002703 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:25466509
   |texte=   Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25466509" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.